Vivoryon Therapeutics N.V. Reports H1 2025 Financial Results and Business Updates

Summary by AI BETAClose X

Vivoryon Therapeutics N.V. reported its H1 2025 financial results, revealing zero revenues, consistent with H1 2024. Research and development expenses decreased significantly by EUR 7.5 million to EUR 2.8 million, primarily due to reduced clinical development and production costs. General and administrative expenses also saw a decrease of EUR 0.7 million, landing at EUR 2.8 million. The net loss for the period was EUR 5.5 million, a notable decrease from the EUR 13.6 million loss in H1 2024. The company's cash and cash equivalents totaled EUR 4.8 million as of June 30, 2025, compared to EUR 9.4 million at the end of 2024. A new U.S. patent for varoglutamstat was granted, extending exclusivity through 2044.

Disclaimer*

UK 100

Latest directors dealings